GHK-Cu History and Development: From Discovery to Modern Peptide Therapy

The starting point: a plasma tripeptide that binds copper

GHK is a three-amino-acid peptide, glycyl-L-histidyl-lysine, found in human plasma, saliva and urine, with levels reported to decline with age. The working proposal in the literature is that GHK acts as a copper complex rather than as a free peptide [1].

A 1980 Nature paper by Pickart and colleagues described a plasma tripeptide, abbreviated GHL in that paper, that co-isolated with roughly equimolar copper and about one-fifth molar iron, readily formed complexes with copper(II), and increased uptake of the metal into cultured hepatoma cells. The authors noted that the peptide's structure resembles the copper-binding sites on albumin and alpha-fetoprotein and proposed that it may act as a copper transport factor [3].

What four decades of laboratory work reported

Most of what is said about GHK-Cu comes from laboratory and animal work, summarized in reviews by the researchers who proposed the mechanism. In those reviews GHK-Cu is reported to stimulate both the synthesis and the breakdown of collagen and glycosaminoglycans, to modulate metalloproteinases and their inhibitors, and to increase collagen, dermatan sulfate, chondroitin sulfate and the small proteoglycan decorin [1]. It is reported to attract immune and endothelial cells to an injury site and to accelerate wound healing in dogs, with systemic wound healing reported in rats, mice and pigs [1].

The peptide is described as capable of up- and downregulating at least 4,000 human genes [1]. A separate review by the same group lists anti-inflammatory actions: suppression of free radicals, thromboxane formation, release of oxidizing iron, transforming growth factor beta-1, tumor necrosis factor alpha and protein glycation, alongside increased superoxide dismutase. That review also reports increased synthesis of collagen, elastin, vascular endothelial growth factor, fibroblast growth factor 2, nerve growth factor and erythropoietin, and increased proliferation of fibroblasts and keratinocytes, angiogenesis and hair follicle size [8].

Animal work has continued in specific disease models. In mice given lipopolysaccharide to injure the lung, GHK-Cu reduced reactive oxygen species, increased superoxide dismutase activity, lowered TNF-alpha and IL-6, and reduced inflammatory cell infiltration into lung tissue [9].

The reviews report cosmetic findings in people, including firmer skin and fewer fine lines [1][8]. They do not establish how well those findings apply to other uses of GHK-Cu.

What the human trials actually showed

A human test of GHK-Cu for a medical wound was a prospective randomized, evaluator-blinded trial published in 1992. Eighty-six evaluable patients with venous stasis ulcers were treated with a 0.4% tripeptide copper complex cream, an inert vehicle placebo, or silver sulfadiazine 1%. Silver sulfadiazine reduced ulcer size compared with both other arms; the copper tripeptide cream was no different from placebo [6].

A 2006 randomized study looked at skin resurfaced with a carbon dioxide laser. Thirteen patients completed it. Computer analysis and blinded evaluators found no statistically significant difference between the GHK-Cu and control groups for earlier resolution of redness, and all patients improved in wrinkles and overall skin quality with no difference between groups. The patient questionnaire did show a significant difference in overall skin quality favoring GHK-Cu (P=.04) [7].

A 2026 systematic review covering 2005 to 2026 screened 1,247 records and retained 64. Its authors describe the human literature as thin and fragmented: most randomized trials are small, are run on facial cosmetic creams, and microneedle delivery has not been evaluated in a single registered, adequately powered human randomized controlled trial [10].

There is no FDA-approved dose or product. Topical cosmetic strengths are set by manufacturers and are not FDA-reviewed, and the only drug-style human trial found used a 0.4% cream [6].

How it became a cosmetic and, separately, a compounded product

Under the federal Food, Drug, and Cosmetic Act, cosmetics and cosmetic ingredients other than color additives do not need FDA approval before they are sold, so copper peptide serums and creams are sold without FDA approval. Whether a product is a cosmetic or a drug depends on intended use: claims to treat disease, or to change the structure or function of the body, make it a drug, and the law does not recognize 'cosmeceutical' as a category [4]. HealthRX.com offers a copper peptide cream.

No FDA-approved drug is known to contain GHK-Cu, and compounded drugs are not FDA-approved — FDA does not verify their safety, effectiveness or quality before they are marketed [2][11].

FDA's list for state-licensed pharmacies and physicians carries 'GHK-Cu (except for injectable routes of administration)' in category 1, the group under evaluation for the bulks list, where FDA says it generally does not intend to act against compounders that meet the conditions in its guidance [2][12]. That entry was removed on April 22, 2026 when the nominations were withdrawn, and added back with a list update on May 14, 2026 after a nominator clarified that it had withdrawn only the injectable route [2].

Injectable GHK-Cu is handled separately. FDA's page on bulk substances that may present significant safety risks, with content dated 04/22/2026, lists 'GHK-Cu (for injectable routes of administration)' among nominations that were withdrawn, with the statement that compounded injectable drugs containing GHK-Cu may pose a risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations [5]. Injectable GHK-Cu is not in category 1 or in any category on FDA's current list [2].

FDA has said it intends to consult its Pharmacy Compounding Advisory Committee before the end of February 2027 about whether GHK-Cu belongs on the pharmacy bulks list. No vote has taken place [2]. GHK-Cu is also a different compound from copper histidinate (Zycubo), which FDA approved on January 12, 2026 for Menkes disease in children [13].

What is known about safety

No adverse-event rates were found in the reports of the two topical trials [6][7]. FDA's immunogenicity concern about compounded injectable GHK-Cu is described above [5].